Skip to main content

Advertisement

Table 1 Prevalence of polypharmacy and of the main drugs prescribed, Colaus study, Switzerland, 2009–2012, 4938 participants

From: Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study

  Frequency n (%) 95% CI
Any drug 2947 (59.7) (58.3–61.1)
Polypharmacy (≥5 drugs) 580 (11.8) (10.9–12.7)
Excessive polypharmacy (≥10 drugs) 69 (1.4) (1.1–1.8)
Cardiovascular 1843 (37.3) (36.0–38.7)
 Antihypertensive drugs 1327 (26.9) (25.6–28.1)
  Angiotensin receptor blockers 644 (13.0) (12.1–14.0)
  Beta-blockers 444 (9.0) (8.2–9.8)
  Angiotensin converting enzyme inhibitors 350 (7.1) (6.4–7.8)
  Calcium channel blockers 229 (4.6) (4.1–5.3)
  Diuretics 158 (3.2) (2.7–3.7)
  Other 81 (1.6) (1.3–2.0)
 Hypolipidemic drugs 1029 (20.8) (19.7–22.0)
  Statins 861 (17.4) (16.4–18.5)
  Other hypolipidemic drugs 219 (4.4) (3.9–5.0)
 Antiplatelet drugs 572 (11.6) (10.7–12.5)
  Aspirin 527 (10.7) (9.8–11.6)
 Vitamin K antagonists 108 (2.2) (1.8–2.6)
Psychiatric 781 (15.8) (14.8–16.9)
 Antidepressants 516 (10.5) (9.6–11.3)
 Anxiolytics 243 (4.9) (4.3–5.6)
 Hypnotics and sedatives 230 (4.7) (4.1–5.3)
 Antipsychotics 54 (1.1) (0.8–1.4)
Analgesics 657 (13.3) (12.4–14.3)
 Anilides 110 (2.2) (1.8–2.7)
 Non-steroidal anti-inflammatory drugs 447 (9.1) (8.3–9.9)
 Opioids 61 (1.2) (0.9–1.6)
Vitamins and minerals 616 (12.5) (11.6–13.4)
Gastro-intestinal Drugs 469 (9.5) (8.7–10.3)
 Antiacids 351 (7.1) (6.4–7.9)
 Drugs for constipation 68 (1.4) (1.1–1.7)
 Othera 114 (2.3) (1.9–2.8)
Antidiabetic drugs 274 (5.6) (4.9–6.2)
 Oral antidiabetics 252 (5.1) (4.5–5.8)
 Insulin 59 (1.2) (0.9–1.5)
  1. aATC codes A01, A03, A04, A05, A07 and A09. Results are expressed as number of participants (percentage) and as 95% confidence interval (CI)